Education
About Us
Working with TipRanks
Follow Us
Getinge AB (GNGBY)
OTHER OTC:GNGBY
Top Page
Getinge AB
(OTC:GNGBY)
Rating:73Outperform
Price Target:
$22.00
▲(11.73%Upside)
Getinge AB (GNGBY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.34B
Dividend Yield0.25%
Average Volume (3M)399.00
Price to Earnings (P/E)37.0
Beta (1Y)0.58
Revenue Growth9.03%
EPS Growth-40.47%
CountryUS
Employees11,827
SectorHealthcare
Sector Strength39
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.20
Shares Outstanding254,152,370
10 Day Avg. Volume52
30 Day Avg. Volume399
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue0.18
Enterprise Value/Gross Profit0.39
Enterprise Value/Ebitda1.04
Forecast
1Y Price Target
$22.00Price Target Upside11.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Getinge AB Business Overview & Revenue Model
Company DescriptionGetinge AB is a leading global provider of medical technology products and services, headquartered in Gothenburg, Sweden. The company operates primarily in the healthcare and life sciences sectors, offering solutions that enhance the quality of care and patient outcomes. Getinge's core products and services include equipment for surgical workflows, intensive care units, and infection control, alongside advanced systems for sterile supply, and life science applications.
How the Company Makes MoneyGetinge AB generates revenue through the sale of its medical technology products and related services across various healthcare and life science sectors. The company's key revenue streams include the sales of equipment for operating rooms and intensive care units, such as ventilators, anesthesia systems, and surgical tables. Additionally, Getinge offers infection control solutions, including sterilization equipment and washer-disinfectors, which are integral to hospital operations. The company also provides service contracts, spare parts, and consumables associated with its products, which contribute to a recurring revenue model. Significant partnerships with healthcare institutions and research organizations globally further bolster its market presence and revenue generation.
Getinge AB Earnings Call Summary
Earnings Call Date:Jul 18, 2025
(Q2-2025)
| % Change Since: 1.49%|
Next Earnings Date:Oct 21, 2025
Earnings Call Sentiment Neutral
The earnings call highlights strong organic growth and margin improvements, successful product launches, and a solid financial position. However, significant challenges from tariffs, currency fluctuations, and geopolitical uncertainties are noted. Despite these headwinds, the company remains optimistic about its growth outlook.Q2-2025 Updates
Positive Updates
Organic Sales and Order Growth
Net sales grew by 4.1% organically with positive development in all business areas and regions. Order intake increased by 4.4% organically.
Margin Improvement
Adjusted gross and EBITA margins improved due to acquisitions, healthy price increases, and positive mix, with EBITA margin rising to 12%.
Successful Product Launches
Paragonix celebrated its 100th kidney transplant case with KidneyVault. Several new products were introduced, including the XEN disinfection chemistry portfolio in the U.S.
Solid Financial Position
Financial leverage remains below 2.5x EBITDA despite increased net debt. Free cash flow amounted to SEK 0.5 billion.
Negative Updates
Tariffs and Currency Impact
Tariffs and currency fluctuations had a significant negative impact on EBITA margin, with tariffs costing approximately minus SEK 110 million in the quarter.
Challenges in Life Science Segment
Softer performance in Life Science based on high comps from the previous year.
Impact of Geopolitical Uncertainty
Uncertainty in trade regulations between EU and China with potential future impacts on tariffs and production costs.
Company Guidance
In the recent conference call, the company provided guidance for 2025, emphasizing their strategic goals and financial expectations. They reiterated their target of achieving at least 12% adjusted EPS growth on average from 2024 to 2028. The strategy involves enhancing sales from recurring revenue, focusing on higher-margin products, and maintaining quality processes. The company reported a positive trend with 65% of sales now coming from recurring revenue and high-margin products constituting approximately two-thirds of sales. The second quarter saw a 4.1% organic net sales growth and a 4.4% increase in order intake, with improvements in adjusted gross and EBITA margins driven by acquisitions and pricing strategies, despite challenges from tariffs and currency fluctuations. The financial outlook for 2025 anticipates an organic net sales growth between 2% to 5%, supported by ongoing productivity improvements and strategic investments.Getinge AB Financial Statement Overview
Summary
Getinge AB demonstrates a stable financial position with strong profitability and a robust balance sheet. However, challenges in revenue growth and free cash flow decline slightly impact its overall financial health. Despite these challenges, the company maintains strong operational efficiency and low leverage, supporting its resilience in the medical devices industry.Income Statement
Getinge AB has demonstrated solid performance in its income statement metrics. The gross profit margin for TTM (Trailing-Twelve-Months) stands at 46% and the net profit margin at 4.16%, indicating healthy profitability levels. However, the revenue growth rate for TTM is 2.32%, which shows moderate growth compared to previous periods. The EBIT margin is 7.79%, and the EBITDA margin is 17.28%, reflecting stable operational efficiency. Overall, the company maintains strong margins but exhibits limited revenue growth, which slightly dampens the score.75
Positive
Balance Sheet
Getinge AB's balance sheet is robust with a debt-to-equity ratio of 0.38, indicating a conservative approach to leverage. The return on equity (ROE) for TTM is 4.84%, which is moderate, considering industry standards. The equity ratio is 50.68%, which demonstrates a strong equity base supporting its assets. The company maintains a solid financial structure with low leverage and a strong equity position, contributing to a high score in this vertical.80
Positive
Cash Flow
The cash flow analysis for Getinge AB reveals mixed results. The free cash flow for TTM has decreased, leading to a negative growth rate of -24.02% compared to the previous year. However, the operating cash flow to net income ratio is 2.57, indicating strong cash generation relative to net income. The free cash flow to net income ratio is 1.68, showing efficient conversion of profit to cash. While operational cash generation remains strong, the decline in free cash flow growth impacts the overall score.70
Positive
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 34.76B | 31.83B | 28.29B | 27.05B | 29.82B |
| Gross Profit | 16.15B | 14.49B | 13.41B | 13.58B | 14.72B |
| EBITDA | 5.31B | 5.91B | 5.70B | 6.15B | 7.20B |
| Net Income | 1.64B | 2.41B | 2.49B | 2.97B | 3.24B |
Balance Sheet | |||||
| Total Assets | 63.92B | 53.59B | 52.03B | 44.55B | 45.01B |
| Cash, Cash Equivalents and Short-Term Investments | 2.96B | 2.73B | 5.68B | 4.08B | 6.06B |
| Total Debt | 10.73B | 8.08B | 5.82B | 4.31B | 10.21B |
| Total Liabilities | 30.71B | 23.18B | 21.58B | 19.38B | 23.53B |
| Stockholders Equity | 33.01B | 30.17B | 30.04B | 24.75B | 21.02B |
Cash Flow | |||||
| Free Cash Flow | 3.27B | 1.60B | 2.23B | 5.63B | 6.15B |
| Operating Cash Flow | 4.58B | 2.96B | 3.37B | 6.56B | 7.20B |
| Investing Cash Flow | -4.55B | -6.54B | -1.47B | -1.33B | -1.99B |
| Financing Cash Flow | 504.00M | 511.00M | -500.00M | -7.24B | -297.00M |
Getinge AB Technical Analysis
Negative
19.69
Price Trends
19.77
Negative
19.94
Negative
18.77
Positive
Market Momentum
0.10
Positive
45.10
Neutral
9.41
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GNGBY, the sentiment is Negative. The current price of 19.69 is below the 20-day moving average (MA) of 20.06, below the 50-day MA of 19.77, and above the 200-day MA of 18.77, indicating a neutral trend. The MACD of 0.10 indicates Positive momentum. The RSI at 45.10 is Neutral, neither overbought nor oversold. The STOCH value of 9.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GNGBY.
Getinge AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $31.09B | 55.50 | 22.83% | ― | 9.30% | -14.95% | |
74 Outperform | $17.93B | 20.08 | 7.31% | 1.06% | 3.30% | -2.39% | |
73 Outperform | $5.34B | 36.99 | 4.80% | 0.25% | 9.03% | -40.47% | |
71 Outperform | $46.53B | 54.44 | 16.73% | ― | -5.23% | -40.13% | |
71 Outperform | $22.32B | 35.75 | 9.46% | 1.00% | 0.32% | 64.36% | |
56 Neutral | $25.26B | ― | -7.10% | 3.35% | -0.76% | -55.03% | |
51 Neutral | $7.38B | 0.36 | -65.54% | 2.37% | 16.37% | 0.39% |
* Healthcare Sector Average
Performance Comparison
GNGBY
Getinge AB
19.69
1.47
8.07%
DXCM
Dexcom
76.25
1.00
1.33%
EW
Edwards Lifesciences
80.09
18.08
29.16%
PHG
Koninklijke Philips
26.72
-0.81
-2.94%
STE
Steris
228.43
-8.39
-3.54%
ZBH
Zimmer Biomet Holdings
92.40
-16.17
-14.89%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.